Browse
Submit Data
Databases
API
Help

Dataset Information

25 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancer

ABSTRACT: Interventions: S-1 : day1-14 80mg/m2. CPT-11 : day1 150mg/m2 Cetuximab : day1,8,15 400mg/m2 (1st time) , 250mg/m2 (2nd time or another) to be repeated every 3 weeks Primary outcome(s): response rate Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622216 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancer

Project description:Interventions: Cetuximab: Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1 every 3 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 150mg/m2, day1 Primary outcome(s): Maximum tolerated dose Recommended dose Study Design: Single arm Non-randomized

| 2619160 | ecrin-mdr-crc

Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.

Project description:Interventions: Cetuximab: Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1 and 8 every 3 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 80mg/m2, day1,8 Primary outcome(s): 1) Phase I study To determine the maximum tolerated dose (MTD) and recommended dose (RD) 2) Phase II study Response rate Study Design: Single arm Non-randomized

| 2618747 | ecrin-mdr-crc

Phase II study of cetuximab rechallenge in the third-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Project description:Interventions: cetuximab (first time) 400mg/m2/week, cetuximab (after 2nd time) 250mg/m2/week, irinotecan 150mg/m2/bi-weekly Primary outcome(s): 3-Month Progression Free Survival Rate Study Design: Single arm Non-randomized

| 2626020 | ecrin-mdr-crc

Phase I study of TS-1+irinotecan+cetuximab as the first-line therapy in patients with KRAS wild-type metastatic colorectal cancer

Project description:Interventions: Cetuximab 400mg/m2 Day1, 250mg/m2 Day 8, 15 Irinotecan 100-150mg/m2/Day1 S-1 80-120mg/day Day1-14 Primary outcome(s): Recommended Dose Study Design: Single arm Non-randomized

| 2626021 | ecrin-mdr-crc

Safety and efficacy of preoperative chemotherapy with SOX+Cetuximab in patients with liver-only metastases(H2,H3), KRAS-WT from colorectal cancer(KSCC1002)

Project description:Interventions: L-OHP 130mg/m2 i.v. (day1) Cmab 250mg/m2 i.v. (only the first time Cmab 400mg/m2) S-1 80mg/m2 (day1-14) to be repeated every 3 weeks for 4 cycles. Surgery was planned after SOX+Cetuximab therapy. Primary outcome(s): Liver resection rate Study Design: Single arm Non-randomized

| 2619781 | ecrin-mdr-crc

Cetuximab plus S-1 and irinotecan (IRIS) as first-line treatment in RAS wild type metastatic colorectal cancer, a phase I/II trial (KSCC1401)

Project description:Interventions: Phase I: IRIS + cetuximab S-1 80-120mg day1-14 Irinotecan 120-150mg/m2 day1 Cetuximab 250mg/m2 day1,8,15 (initial dose:400mg/m2) administered every 3 weeks until PD Phase II: IRIS + cetuximab Administered the RD fixed in Phase I Primary outcome(s): Phase I: maximum tolerated dose (MTD) and recommended dose (RD) Phase II: objective response rate Study Design: Single arm Non-randomized

| 2631161 | ecrin-mdr-crc

Phase1 trial of Cetuximab/S-1 combination therapy for Advanced/Recurrent Colorectal Cancer

Project description:Interventions: cetuximab S-1 combination therapy cetuximab : Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) S-1 : 60 or 80 mg/m2/2weeks/day1-14, 4weeks Primary outcome(s): To determine the recomend dose of cetuximab and S-1 combinaton therapy Study Design: Single arm Non-randomized

| 2619576 | ecrin-mdr-crc

Multicenter Phase II trial of Irinotecan plus S-1 with cetuximab (IRIS/Cet) in patients with EGFR positive and KRAS wild type of advanced/metastatic colorectal cancer

Project description:Interventions: Irinotecan plus S-1 with cetuximab combination therapy Cetuximab 400mg/m2 day1 and then 250mg/m2 day 8,15,22 weekly until PD, or Cetuximab 500mg/m2 day 1, 15, 29 biweekly until PD Irinotecan 100 mg/m2 day1,15, 30 biweekly until PD S-1 S-1 80mg [BSA<1.25m2] or 100mg [1.25m2<BSA<1.5m2] or 120mg [1.5m2<BSA]/body/day, day 1-14, q4weeks Primary outcome(s): Response rate Study Design: Single arm Non-randomized

| 2620325 | ecrin-mdr-crc

Multicenter Phase II study of combination therapy with S-1 plus Irinotecan plus Cetuximab (MetronomicIRIS/Cmab combination therapy) in patients with KRAS wild type unresectable colorectal cancer, who had previously received on fluoropyrimidine , oxaliplatin , irinotecan and bevacizumab. (KSCOG CR-06)

Project description:Interventions: MetronomicIRIS(S-1/CPT-11)/Cmab combination therapy S-1:50 or 60 or 80mg/body/day(day3-7,10-14,17-21,24-28) CPT-11:60mg/m2(day1,8,15) Cmab*:250mg/m2(day1,8,15,22) *:400mg/m2 for the initial dosing(day1) every 4 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

| 2627425 | ecrin-mdr-crc

mFOLFOX6+Cetuximab in Treating Patients With not Optimally Resectable Liver Metastases From Colorectal Cancer

Project description:Interventions: mFOLFOX6Cetuximab Neoadjuvant 6course Adjuvant 6course Cetuximab loading dose 400mg/m2 weekly 250mg/m2/week LOHP 85mg/m2/day1 lLV 200mg/m2/day1 bolus 5FU 400mg/m2/day1 infusional 5FU 2400mg/m2/day1-3 Primary outcome(s): overall response rate Study Design: Single arm Non-randomized

| 2620254 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data